TransCelerate adds two members, appoints chair

Not-for-profit biopharma consortium TransCelerate BioPharma Inc. (Philadelphia, Pa.) added Merck & Co. Inc. (NYSE:MRK) and Novo Nordisk A/S (CSE:NVO; NYSE:NVO) as member companies. Merck acquired TransCelerate member Cubist Pharmaceuticals Inc. last week.

The consortium also named as its chairman Briggs Morrison, who is EVP of global medicines development at AstraZeneca plc (LSE:AZN; NYSE:AZN). He succeeds Annalisa Jenkins, who became chair in February 2014 but stepped down last year after leaving the Merck Serono unit of Merck KGaA (Xetra:MRK), a TransCelerate member. ...